New York Times
The supply of low-cost, generic versions of cancer and AIDS treatments
for the developing world could be blocked if Novartis wins a legal
challenge to India's patent law, patients' rights groups have contended.
But Western drug companies say that if Novartis loses its challenge,
their ability to invest in the research and development of new medicines
will be severely hampered. ... FULL STORY